CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 3,217 enrolled
Drug / intervention
Chloroquinedrug
Likely dose
Chloroquine 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04627467
NCT04627467Phase 2Completed
CompareCT.gov

Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19)

Fundacion Clinica Valle del Lili·interventional·Posted Nov 13, 2020·Updated Oct 7, 2021

In Brief

A Phase 2 clinical trial evaluating Chloroquine for Covid19. Completed, enrolled 3,217 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the efficacy and safety of chloroquine prophylaxis on the incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections in healthcare workers exposed to patients with confirmed Coronavirus Disease 2019 (COVID-19)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesColombia
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 13, 2020
Enrollment StartMar 28, 2020
Primary CompletionJul 9, 2020
Study CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.6 years ago

Interventions

Chloroquinedrug

250mg tablet (150mg base chloroquine)